Boehringer In­gel­heim joins the crowd and goes all-in on on­colyt­ic virus­es, buy­ing Vi­raTher­a­peu­tics in $244M deal

Boehringer In­gel­heim de­cid­ed 3 years ago it that would take an ac­tive role in fos­ter­ing the on­colyt­ics virus biotech Vi­raTher­a­peu­tics. 

The Ger­man com­pa­ny’s ven­ture arm in­vest­ed in the fledg­ling’s biotech’s tiny $4 mil­lion A round in the sum­mer of 2015. BI ex­ecs came back with a $230 mil­lion dis­cov­ery deal — build­ing in a buy­out op­tion — and then added a sec­ond pro­gram. And this morn­ing they’re go­ing all in, buy­ing the com­pa­ny in a deal val­ued at $244 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.